Amazingly solid despite the stalls and jitters....this IS the new base before the next leg up to 8+ cents IMO.
Really surprising to me is that I found a second gem just 3 weeks ago with so much similarity to the October situation of RXMD (resp to debt payoff, double zero pps, communicating management, YOY and QoQ growth., even better share structure OS80M, annual revs in 2016 of 4M expected, expansion, longs semi-locking 50% of the float etc. etc.)
Its SVTE , so similarly to RXMD in october I loaded SVTE last week and just in time because it went up 70% throughout April and just last friday 40% alone. Its prob. leaving the double zero/1 cent threshhold behind next week and will climb to its fair current evaluation of 10+cent with few consolidations.
I considered myself smart and lucky to get it just right with RXMD and now, totally contrary to expectations with respect to OTC, I am not only sitting on one but two Gems IMO and I really feel that with these two long term-legs I can turn my back for good to the higher exchanges and be pretty safe on the OTC yet drive larger gains.
Really surprising to me is that I found a second gem just 3 weeks ago with so much similarity to the October situation of RXMD (resp to debt payoff, double zero pps, communicating management, YOY and QoQ growth., even better share structure OS80M, annual revs in 2016 of 4M expected, expansion, longs semi-locking 50% of the float etc. etc.)
Its SVTE , so similarly to RXMD in october I loaded SVTE last week and just in time because it went up 70% throughout April and just last friday 40% alone. Its prob. leaving the double zero/1 cent threshhold behind next week and will climb to its fair current evaluation of 10+cent with few consolidations.
I considered myself smart and lucky to get it just right with RXMD and now, totally contrary to expectations with respect to OTC, I am not only sitting on one but two Gems IMO and I really feel that with these two long term-legs I can turn my back for good to the higher exchanges and be pretty safe on the OTC yet drive larger gains.
